Skip to main content
Equibles
CHRS logo

CHRS · Coherus Oncology, Inc. · Metrics

Track CHRS — free

Use CHRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CHRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.77 +0.02 (+2.82%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$118.97M
Shares
154.50M
Volume · Nov 6 1.08M Avg daily vol (3M) 1.45M

CHRS metrics

91 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.77
Market cap
$118.97M

Price action

23 metrics
Price change (1W)
-16.6%
Price change (30D)
-25.9%
Price change (3M)
-40.8%
Price change (6M)
-57.4%
Price change (YTD)
-47.3%
Price change (1Y)
-52.1%
Trailing year
Price change (5Y)
-95.8%
52-week high
$2.51
52-week low
$0.75
Change from 52-week high
-70.2%
Change from 52-week low
+0.0%
Annualized volatility
85.4%
Annualized volatility (3M)
96.0%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.0
RSI (14D)
34.5
Price vs SMA 50
-34.8%
Price vs SMA 200
-50.5%
Avg volume (3M)
1.49M
Relative volume
1.2
Average dollar volume
$1.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
154.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.3×
reciprocal yield 44.0%
P / book
1.9
reciprocal yield 52.6%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-114.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.8×
reciprocal yield 36.4%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 36.4%
EV / EBIT historical average (3Y)
7.7×
reciprocal yield 12.9%
EV / EBIT historical average (5Y)
7.7×
reciprocal yield 12.9%
EV / EBITDA historical average (3Y)
7.6×
reciprocal yield 13.2%
EV / EBITDA historical average (5Y)
7.6×
reciprocal yield 13.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-09
Last earnings
2026-10-28

Profitability

9 metrics
Gross margin
68.9%
Operating margin
-311.6%
Trailing 12 months
Net margin
-259.4%
Gross profit (TTM)
$35.11M
Operating profit (TTM)
−$158.69M
Net income (TTM)
−$132.13M
Trailing 12 months
Diluted EPS (TTM)
$-4.12
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.39
Gross profit per diluted share (TTM)
$0.27
Operating profit per diluted share (TTM)
$-1.24
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.03
Operating cash flow per diluted share (TTM)
$-1.39
Free cash flow per diluted share (TTM)
$-3.15
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.79
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.50

Growth

11 metrics
Revenue growth YoY
+39.5%
Year over year
Net income growth YoY
-106.9%
Revenue (TTM)
$50.94M
Trailing 12 months
EPS growth YoY
-105.1%
Shares change YoY
+33.4%
Year over year · more shares
Revenue CAGR (3Y)
-41.5%
Revenue CAGR (5Y)
-38.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-2.5%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-217.2%
Return on assets
-69.1%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
−$156.35M
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
-17.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$82.92M
Total assets
$191.18M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$186.03M
Capital expenditures (TTM)
$286,000
R&D (TTM)
$101.21M
SG&A (TTM)
$92.60M
Stock compensation (TTM)
$11.14M
R&D / revenue
198.7%
Stock compensation / revenue
21.9%

Ownership (13F)

9 metrics
13F filers
147
13F filer change QoQ
-12
Institutional ownership
45.6%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
11.6%
Private-fund adviser ownership
11.1%
Active holders' share change QoQ
-9.1%
Holder tenure
10.6
Price vs estimated holder cost
-23.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.9%

Short interest

3 metrics
Short interest
8.1%
Latest settlement · 7.9 days to cover
Days to cover
7.9d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 72 filings 49 filers Visit website Investor relations